A method for simultaneously determining multiple drug components in a biological sample based on LC-MS / MS technology

By using liquid chromatography-mass spectrometry (LC-MS/MS) for pretreatment and detection of biological samples, the challenge of simultaneously determining multiple drug components has been solved, enabling rapid and accurate drug concentration determination and improving the accuracy of therapeutic drug monitoring and drug interaction studies.

CN119901852BActive Publication Date: 2026-11-10GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510145158.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-02-10
Publication Date
2026-11-10
Estimated Expiration
2045-02-10

AI Technical Summary

Technical Problem

Existing technologies make it difficult to rapidly and accurately determine the concentrations of multiple drug components in biological samples simultaneously, affecting the accuracy of therapeutic drug monitoring and drug interaction studies.

Method used

Liquid chromatography-mass spectrometry (LC-MS/MS) was used for the pretreatment and detection of biological samples, including protein precipitation to remove interfering substances and optimization of chromatographic and mass spectrometric parameters to achieve simultaneous determination of multiple drug components.

Benefits of technology

It enables rapid and accurate simultaneous determination of phenytoin sodium, palmiridon, voriconazole, theophylline, fluvoxamine, and lidocaine, with high sensitivity and accuracy, and is suitable for therapeutic drug monitoring and drug interaction studies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119901852B_ABST
    Figure CN119901852B_ABST
Patent Text Reader

Abstract

The application discloses a method for synchronously determining multiple drug components in a biological sample based on LC-MS / MS technology, wherein the multiple drugs are phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine; the method comprises the following steps: obtaining a biological sample and performing pretreatment on the biological sample; and adopting liquid chromatography mass spectrometry technology to synchronously detect phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine in the sample. The method can realize rapid synchronous determination of phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine, and has high sensitivity and accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of drug detection, specifically relating to a method for simultaneously determining multiple drug components in biological samples based on LC-MS / MS technology. Background Technology

[0002] Therapeutic drug monitoring (TDM) is a method that measures drug concentrations in a patient's body to develop individualized dosing regimens, aiming to improve drug efficacy and safety. TDM can enhance the effectiveness of drug therapy, reduce adverse reactions, and provide a basis for the diagnosis and management of drug overdose, making it an important means of achieving individualized treatment. During drug therapy, it is necessary to regularly monitor drug concentrations in patients' bodies to adjust dosages in a timely manner and improve treatment outcomes.

[0003] Phenytoin sodium is a widely used antiepileptic drug, belonging to the IB class of antiarrhythmic drugs. Due to its membrane stability, it inhibits the rapid influx of sodium ions. Phenytoin sodium primarily works by stabilizing neuronal cell membranes and inhibiting sodium ion influx. + Channel and rapid inactivation of Ca 2+ Channels, thereby inhibiting Ca 2+ Inflow and K + It effectively inhibits abnormal high-frequency discharge by efflux. Phenytoin sodium is used clinically for anti-epileptic, treatment of trigeminal neuralgia and sciatica, antiarrhythmic, and antihypertensive effects.

[0004] Paliperidone is an atypical antipsychotic drug primarily used to treat schizophrenia and schizoaffective disorder. It exerts its antipsychotic effects by blocking dopamine D2 receptors and serotonin 2A receptors in the central nervous system.

[0005] Voriconazole is a broad-spectrum antifungal drug primarily used to treat invasive aspergillosis, severe infections caused by fluconazole-resistant Candida species, and severe infections caused by Actinobacter spp. and Fusarium spp.

[0006] Theophylline is a commonly used drug for treating respiratory diseases such as bronchial asthma and wheezing bronchitis. Theophylline primarily works by inhibiting phosphodiesterase (PDE), increasing the intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), thereby relaxing bronchial smooth muscle and relieving wheezing symptoms. Theophylline is mainly used to treat respiratory diseases such as bronchial asthma, wheezing bronchitis, and obstructive emphysema, relieving wheezing symptoms. In addition, theophylline also has anti-inflammatory and immunomodulatory effects, enhancing diaphragmatic contractility and improving respiratory function. However, theophylline has a narrow therapeutic window, and even small changes in blood drug concentration can lead to differences in efficacy and safety. Therefore, monitoring theophylline blood concentration is crucial to ensuring patient safety and efficacy.

[0007] Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat depression and obsessive-compulsive disorder, but it can also be used to treat anxiety disorders, panic disorders, and social anxiety disorders. Fluvoxamine exerts its antidepressant and anti-anxiety effects by inhibiting the reuptake of 5-HT from the presynaptic membrane, increasing the concentration of 5-HT in the synaptic cleft, and enhancing the conduction of serotonergic neurons.

[0008] Lidocaine is a local anesthetic and antiarrhythmic drug, commonly used for surface anesthesia, infiltration anesthesia, nerve conduction blocks, and the treatment of ventricular arrhythmias. Lidocaine achieves its local anesthetic effect by blocking sodium channels and inhibiting nerve signal transmission. As a class IB antiarrhythmic drug, low doses of lidocaine promote potassium ion efflux from cardiomyocytes, reducing myocardial automaticity and thus exhibiting antiarrhythmic activity.

[0009] During treatment, a convenient, rapid, and accurate method for separation and determination is needed to simultaneously measure the concentrations of multiple drugs, thereby facilitating therapeutic drug monitoring, drug interaction studies, and pharmacological analysis. Summary of the Invention

[0010] The purpose of this invention is to address the above-mentioned technical problems by providing a convenient, rapid, accurate, and simultaneous method for determining the drug components phenytoin sodium, palpanidone, voriconazole, theophylline, fluvoxamine, and lidocaine in biological samples.

[0011] To achieve the above-mentioned objectives, this invention provides a method for the simultaneous determination of multiple drug components in biological samples based on LC-MS / MS technology. The multiple drug components include phenytoin sodium, palpanidone, voriconazole, theophylline, fluvoxamine, and lidocaine. The method comprises the following steps: S1. Obtain biological samples and pre-treat them; S2. Phenytoin sodium, palpanidone, voriconazole, theophylline, fluvoxamine, and lidocaine were detected simultaneously in the sample using liquid chromatography-mass spectrometry.

[0012] In a preferred embodiment, the biological sample is serum.

[0013] As a preferred embodiment, the pretreatment step in step S1 is as follows: 100 μL of mixed internal standard solution is added to 100 μL of biological sample, equilibrated for 5 minutes, then 1 mL of acetonitrile is added for protein precipitation, mixed well, and then centrifuged at 12000 rpm for 10 minutes. 1 mL of the supernatant is then added to 500 μL of 50% methanol aqueous solution, centrifuged at 12000 rpm for 2 minutes, and 200 μL of the supernatant is added to 1 mL of 50% methanol aqueous solution.

[0014] As a preferred embodiment, the preparation steps of the mixed internal standard solution are as follows: dilute the internal standard stock solution with a concentration of 100 µg / mL with methanol of a volume concentration of 50% to prepare a mixed internal standard solution of phenytoin sodium, palpanidone, voriconazole, theophylline, fluvoxamine, and lidocaine isotopes.

[0015] In a preferred embodiment, the mixed internal standard solution contains phenytoin sodium at a concentration of 0.8 µg / mL, palapirone at a concentration of 50 ng / mL, voriconazole at a concentration of 2.0 µg / mL, theophylline at a concentration of 5 µg / mL, fluvoxamine at a concentration of 200 ng / mL, and lidocaine at a concentration of 2.0 µg / mL.

[0016] In a preferred embodiment, the liquid chromatography conditions in step S2 are as follows: the chromatographic column is a Phenomen Kinetex 100*2.10 mm, 2.6 μm; the column temperature is 40 °C. o C; flow rate: 300 μL / min; injection volume: 5 μL; organic phase: acetonitrile; aqueous phase: 0.1% formic acid + 0.2 mM ammonium formate.

[0017] The gradient elution conditions are as follows: .

[0018] As a preferred implementation method, the mass spectrometry detection ion parameters are as follows: .

[0019] As a preferred embodiment, the gas parameters for mass spectrometry detection are as follows: curtain gas is 35 au, collision gas is 7 au, ion spray voltage is 5500 volts, temperature is 500°C, ion source gas 1 is 50 au, and ion source gas 2 is 50 au.

[0020] The method of this invention can achieve rapid and simultaneous determination of phenytoin sodium, palmide, voriconazole, theophylline, fluvoxamine, and lidocaine, with high sensitivity and accuracy. Attached Figure Description

[0021] Figure 1 This is a chromatogram of six therapeutic monitoring drugs detected simultaneously using LC-MS / MS technology. Detailed Implementation

[0022] The present invention will be further described below with reference to specific embodiments. It should be understood that the following embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.

[0023] 1 Reagent 1.1 Standard Products Phenytoin sodium (Supelco; PHR1139, purity 96.40%) Palpiridone (CATO; 144598-75-4, purity 98.60%) Theophylline (LGC; 58-55-9, purity 98.08%) Fluvoxamine (LGC; 61718-82-9, 99% purity) Voriconazole (LGC; MM194.00, purity 99.60%) Lidocaine (J&K; 137-58-6, 99% purity) 1.2 Internal Standard Phenytoin sodium internal standard (Phe-D10) (Cerilliant; P-067-1ML, 100 μg / mL) Palpiridone internal standard (Pal-D4) (Supelco; 1020719-55-4, 100 μg / mL) Theophylline internal standard (The-IS) (CIL; 100 MILLIGRAMS, 2- 13 C, 99%; 1, 3- 15 N2, 98%+) Fluvoxamine internal standard (Flu-D3) (Cerilliant; 1185245-56-0; Fluvoxamine-D3, 100 µg / mL) Vorconazole internal standard (Vor-D3) (CATO; CCAD301239, 99.7%) Lidocaine internal standard (Lid-D10) (MCE; 851528-09-1, 98.9%) 1.3 Organic solvents: Acetonitrile and methanol, chromatographic grade or better.

[0024] 50% methanol refers to an aqueous solution of methanol with a volume concentration of 50%.

[0025] 2. Preparation Operation 2.1 Preparation Requirements All substances used to prepare solutions refer to 100% purity. If the purity is insufficient, the purity should be converted accordingly.

[0026] Conversion formula:

[0027] g 实际 : The actual mass of the raw material, in grams (g).

[0028] g 理论 Theoretical mass of raw materials, in grams (g).

[0029] z: Percentage of raw material purity, % The standard for water used in preparation is: resistance > 10 ohms at 25℃. 6 cm of deionized water or double-distilled water.

[0030] 2.2 Preparation of mobile phase 2.2.1 Aqueous phase: 0.1% formic acid + 0.2mM ammonium formate (add 1mL formic acid and 1mL of 200mM ammonium formate stock solution to 998mL of pure water) 2.2.2 Organic phase: pure acetonitrile 2.3 Preparation of working standard samples The stock solution of the drug standard was diluted with 50% methanol to prepare working standards with the drug concentrations shown in Table 1 below: Table 1: Drug Concentration of Working Standards

[0031] 2.4 Preparation of internal standard solution Preparation of the target working solution (ISWS) for the internal standard: The stock solution of the drug internal standard (100 µg / mL) was diluted with 50% (v / w) methanol to prepare mixed internal standards of phenytoin sodium, palmide, voriconazole, theophylline, fluvoxamine, and lidocaine isotopes, with concentrations of 0.8 µg / mL, 50 ng / mL, 2.0 µg / mL, 5 µg / mL, 200 ng / mL, and 2.0 µg / mL, respectively.

[0032] 3. Instruments and Equipment The system includes an AB / Sciex API 5500 tandem Shimadzu LC-20AD XR liquid chromatography-mass spectrometry system, a centrifuge, an ultrasonic cleaner, a Sartorius CP225D analytical balance, a Millipore pure water system, Eppendorf pipettes, and a magnetic stirrer.

[0033] 4. Sampling and Samples 4.1 Sampling: Vacuum blood collection tubes are used to collect venous blood from the elbow.

[0034] 4.2 Sample: Serum 5. Testing Procedures 5.1 Instrument Preparation 5.1.1 Liquid Chromatography Conditions The six drugs to be detected have different chemical and physicochemical properties. To achieve good separation under the same detection conditions, it is necessary to select a suitable chromatographic column and optimize the mobile phase composition and gradient elution conditions. The final optimization results are shown in Table 2 below.

[0035] Chromatographic column: Phenomen Kinetex 100*2.10 mm, 2.6 μm Mobile phase: Aqueous phase: 0.1% formic acid + 0.2mM ammonium formate; Organic phase: acetonitrile Table 2: Gradient elution conditions for liquid chromatography

[0036] The limits of detection (LODs) and limits of quantitation (LOQs) of the six drugs to be tested are not entirely the same. In particular, the concentrations of palaphinone and fluvoxamine in clinical samples are at the ng / mL level, while the concentrations of the other drugs are at the µg / mL level. Furthermore, the blood concentration ranges of these drugs also vary. To achieve simultaneous detection, it is necessary to select the optimal parent ion-daughter ion pair combination and optimize the mass spectrometer detection parameters (spray voltage, collision energy, curtain gas, etc.) to ensure sufficient sensitivity for all target analytes and maintain good linearity within the linear range. The final optimized results of the mass spectrometry detection ion parameters are shown in Table 3 below.

[0037] Ion source screening: ESI, positive ion mode Ion pair selection: parent ion, daughter ion.

[0038] Table 3: Ion parameters

[0039] Phe: Phenytoin sodium; Phe-IS: Phenytoin sodium internal standard; Pal: Palamridone; Pal-IS: Palamridone internal standard; Vor: Voriconazole; Vor-IS: Voriconazole internal standard; The: Theophylline; The-IS: Theophylline internal standard; Flu: Fluvoxamine; Flu-IS: Fluvoxamine internal standard; Lid: Lidocaine; Lid-IS: Lidocaine internal standard.

[0040] The gas parameters are shown in Table 4 below.

[0041] Table 4: Gas Parameters

[0042] 5.1.2 Instrument equilibration: Equilibrate the instrument according to the set chromatographic mass spectrometry conditions for 30-60 minutes.

[0043] 5.1.3 Set the sample quantity and injection frequency, and select the pre-defined detection method.

[0044] 5.2 Sample Preparation Before the experiment begins, all standard working solutions, internal standard working solutions, and quality control samples should be equilibrated to room temperature. When taking samples of standard working solutions, internal standard working solutions, quality control samples, or test samples, they must be mixed thoroughly, and air bubbles should be avoided as much as possible during mixing.

[0045] 5.2.1 Sample Pretreatment Biological samples contain a large number of endogenous substances, which may cause non-specific adsorption or ion inhibition, thus affecting the accuracy of quantification. Therefore, this method uses protein precipitation in the sample pretreatment process to remove interfering substances, while optimizing the operation steps and simplifying the sample pretreatment process. The specific pretreatment steps are as follows: 1) Add 100 μL of sample and 100 μL of mixed internal standard to a 2 mL EP tube and equilibrate at room temperature for 5 minutes; 2) Add 1 mL of acetonitrile to precipitate the protein and mix well; 3) Centrifuge at 12000 rpm for 10 minutes; 4) Take 1 mL of the supernatant and add 500 μL of 50% methanol aqueous solution; 5) Centrifuge at 12000 rpm for 2 minutes; 6) Take 200 μL of supernatant and put it into 1 mL of 50% methanol aqueous solution.

[0046] 5.2.2 Standard Curve 5.2.2.1. Select two standard solutions for detection and the peak area ratio of their corresponding chromatographic peaks to establish a working curve, with the peak area ratio of the chromatographic peaks as the independent variable and the concentration as the dependent variable.

[0047] 5.2.2.2 The standard curve processing sample system is shown in Table 5 below (samples are added using 5mL EP tubes).

[0048] Table 5: Sample system processed by standard curve

[0049] 5.3 Detection Take 5 μL each of the pretreated serum sample and the mixed standard solution, inject them into a liquid chromatography-mass spectrometry instrument, and determine and calculate the concentrations of the six drugs.

[0050] Figure 1 Chromatograms of six therapeutic monitoring drugs simultaneously detected using LC-MS / MS technology are shown.

[0051] 6. Data Processing 6.1 Establishment of the working curve 1) Establish a working curve by selecting the mass ratio of the two standard solutions and the corresponding peak area ratio of the chromatographic peaks, with the peak area ratio as the independent variable and the concentration ratio as the dependent variable. Calculate the slope 'a' and intercept 'b' of the linear regression equation for the standard curve using the SLOPE (slope) and INTERCEPT (intercept) formulas, respectively, and establish the working curve. y = ax + b y - The concentration of the drug in the sample; x - Peak area ratio of chromatographic peaks; a - The slope of the standard curve linear regression equation; b - The intercept of the linear regression equation of the standard curve.

[0052] 2) Since the same amount of internal standard is added to both the standard and the test sample, the peak area ratio of the chromatographic peaks of the test sample can be obtained, and the corresponding drug concentration can be calculated through the working curve.

[0053] 6.2 Evaluation of Standard Curve 1) Calculate the correlation coefficient r between the peak area ratio and the mass ratio of the standard solution. The peak area ratio of the drug in the standard solution to the IS chromatographic peak was used as the independent variable, and the mass ratio was used as the dependent variable. The correlation coefficient r was calculated using the CORREL formula. 2) r>0.99 indicates that the calibration is qualified. If it does not meet the requirements, the calibration will fail and the standard curve needs to be re-established.

[0054] 7. Measurement Procedure Reliability Analysis 7.1 Accuracy The results of the sample testing accuracy are shown in Table 6 below. Table 6: Sample Detection Accuracy Results

[0055] 7.2 Precision Precision assessment shall be performed in accordance with the Clinical and Laboratory Standards Institute (CLSI) document EP15-A3.

[0056] Serum samples at low, medium, and high concentrations were measured. Intra-assay precision was evaluated using nine parallel assays; inter-assay and overall precision were assessed using a 5×5 method, meaning one batch was tested daily, with each batch containing five parallel samples. Each sample was measured three times, and the average values ​​were taken. A total of 25 values ​​were obtained over five consecutive days. Subsequently, one-way ANOVA was used to calculate inter-assay and intra-assay imprecision, and the coefficient of variation (CV) is typically used to assess precision.

[0057] The results of the precision measurement are shown in Table 7 below.

[0058] Table 7: Sample Detection Precision Results

[0059] 7.3 Linear Range According to CLSI-EP6, the linear range of clinical samples was established by performing eight-point serial dilutions (Low, 0.857L+0.143H, 0.714L+0.286H, 0.571L+0.429H, 0.429L+0.571H, 0.286L+0.714H, 0.143L+0.857H, H) on high-value samples (phenytoin sodium, palpanrenone, voriconazole, theophylline, fluvoxamine, and lidocaine concentrations of 20 μg / mL, 200 ng / mL, 6 μg / mL, 60 μg / mL, 2000 ng / mL, and 5.0 μg / mL, respectively) and blank serum samples (healthy examinees whose blood did not contain the following drugs).

[0060] The results are shown in Table 8 below.

[0061] Table 8: Linear Range Results

[0062] 7.4 Analytical Sensitivity The limit of detection (LOD) is the lowest concentration in a sample that can be reliably detected but may not be accurately quantified.

[0063] The limit of quantification (LOQ) is the lowest concentration of a sample that can be accurately measured to a certain extent.

[0064] This invention selects a series of low-concentration samples and blank serum samples for detection, and uses a signal-to-noise ratio (S / N) ≥ 3 as the standard for the limit of detection; and a signal-to-noise ratio (S / N) ≥ 10 and CV ≤ 20% (n=4) as the standard for the limit of quantitation.

[0065] The test results are shown in Table 9 below.

[0066] Table 9: Results of Limit of Detection and Limit of Quantitation

[0067] 7.5 Interference Experimental testing verified that hemolysis, lipemia, and jaundice had no effect on the drug detection results of this method.

[0068] 7.6 Carrying pollution "Carryover contamination" refers to the discontinuous amount of analyte carried from one sample reaction to another by the measurement system, thereby incorrectly affecting the performance of the other sample. Specifically, it refers to sample carryover. "Biochemical detection system carryover contamination" refers to the process where substances remaining from a previous biochemical test (biological samples, reagents, mixed reaction solutions, or reaction products, etc.) are carried into the next biochemical detection reaction through instrument components (including but not limited to probes, cuvettes, stirring rods, tubing, etc.), participating in the reaction, affecting the reaction process, directly or indirectly interfering with colorimetry or turbidimetry, and leading to significant deviations in the detection results.

[0069] The tests showed that the contamination rates of high-value samples (concentrations of 5 μg / mL, 200 ng / mL, 8 μg / mL, 30 μg / mL, 800 ng / mL, and 8.0 μg / mL, respectively) and medium-value samples (concentrations of 2.5 μg / mL, 100 ng / mL, 4 μg / mL, 15 μg / mL, 200 ng / mL, and 4 μg / mL, respectively) of the six drugs (phenytoin sodium, palpanrenone, voriconazole, theophylline, fluvoxamine, and lidocaine) to low-value samples (concentrations of 0.5 μg / mL, 10 ng / mL, 0.5 μg / mL, 2.5 μg / mL, 20 ng / mL, and 0.5 μg / mL, respectively) were between -0.07% and 0.81% under the conditions of the tests. Therefore, it can be considered that there was no significant contamination under the conditions of the tests.

[0070] The above results demonstrate that the method of the present invention has good accuracy, precision, and sensitivity, and can simultaneously detect the concentrations of six drugs in serum: phenytoin sodium, palmide, voriconazole, theophylline, fluvoxamine, and lidocaine.

[0071] Comparative Example 1 This comparative example provides an LC-MS / MS method for detecting the concentrations of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that the protein precipitant used in the sample pretreatment is replaced with an equal amount of methanol instead of acetonitrile.

[0072] Test results: Worst detection metric R 2 The value is 0.98, the accuracy is 85%, and the precision is 12%.

[0073] Comparative Example 2 This comparative example provides an LC-MS / MS method for detecting the concentrations of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that an equal amount of methanol is used instead of acetonitrile in the mobile organic phase.

[0074] Test results: Worst detection metric R 2 The value is 0.95, the accuracy is 82%, and the precision is 15%.

[0075] Comparative Example 3 This comparative example provides an LC-MS / MS method for detecting the concentration of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that the mobile aqueous phase is replaced with an equal amount of 0.1% formic acid instead of "0.1% formic acid + 0.2mM ammonium formate".

[0076] Test results: Worst detection metric R 2 The value is 0.97, the accuracy is 85%, and the precision is 10%.

[0077] Comparative Example 4 This comparative example provides an LC-MS / MS method for detecting the concentrations of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that the equilibration time between the sample and the internal standard is changed from 5 min to 30 min.

[0078] Test results: Worst detection metric R 2 The value is 0.98, the accuracy is 90%, and the precision is 10%.

[0079] Comparative Example 5 This comparative example provides an LC-MS / MS method for detecting the concentrations of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that the elution conditions for liquid chromatography are changed to isocratic elution (70% B).

[0080] Test results: Worst detection metric R2 The value is 0.95, the accuracy is 80%, and the precision is 15%.

[0081] Comparative Example 6 This comparative example provides an LC-MS / MS method for detecting the concentrations of multiple therapeutic monitoring drugs in biological samples. The only difference between this method and the present invention is that the collision energy for each drug mass spectrometry detection is replaced with 20V and the residence time is replaced with 100msec.

[0082] Test results: Worst detection metric R 2 The value is 0.96, the accuracy is 85%, and the precision is 12%.

Claims

1. A method for simultaneous determination of multiple drug components in biological samples based on LC-MS / MS technology, characterized in that, The various drugs mentioned are phenytoin sodium, palmide, voriconazole, theophylline, fluvoxamine, and lidocaine. The method includes the following steps: S1. Obtain biological samples and pre-treat them; S2. Phenytoin sodium, palapirone, voriconazole, theophylline, fluvoxamine, and lidocaine were simultaneously detected in the sample using liquid chromatography-mass spectrometry. The pretreatment steps in step S1 are as follows: Add 100 μL of mixed internal standard solution to 100 μL of biological sample, equilibrate for 5 minutes, then add 1 mL of acetonitrile for protein precipitation, mix well, then centrifuge at 12000 rpm for 10 minutes, then take 1 mL of supernatant and add it to 500 μL of 50% methanol aqueous solution, centrifuge at 12000 rpm for 2 minutes, and take 200 μL of supernatant in 1 mL of 50% methanol aqueous solution; In step S2, the liquid chromatography conditions are as follows: the chromatographic column is a Phenomen Kinetex 100. 2.10 mm, 2.6 μm; column temperature 40 °C o C; flow rate: 300 μL / min; injection volume: 5 μL; organic phase: acetonitrile; aqueous phase: 0.1% formic acid + 0.2 mM ammonium formate; In step S2, the gradient elution conditions for liquid chromatography are as follows: ; In step S2, the mass spectrometry detection ion parameters are as follows: ; In step S2, the gas parameters for mass spectrometry detection are as follows: curtain gas is 35 au, collision gas is 7 au, ion spray voltage is 5500 volts, temperature is 500℃, ion source gas 1 is 50 au, and ion source gas 2 is 50 au.

2. The method according to claim 1, characterized in that, The biological sample is serum.

3. The method according to claim 1, characterized in that, The preparation steps of the mixed internal standard solution are as follows: dilute the internal standard stock solution with a concentration of 100 µg / mL with methanol of a volume concentration of 50% to prepare a mixed internal standard solution of phenytoin sodium, palpanidone, voriconazole, theophylline, fluvoxamine, and lidocaine isotopes.

4. The method according to claim 3, characterized in that, In the mixed internal standard solution, the concentrations of phenytoin sodium internal standard were 0.8 µg / mL, palapirone internal standard were 50 ng / mL, voriconazole internal standard were 2.0 µg / mL, theophylline internal standard were 5 µg / mL, fluvoxamine internal standard were 200 ng / mL, and lidocaine internal standard were 2.0 µg / mL.

Citation Information

Patent Citations

  • Method for detecting antifungal drugs in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology

    CN111766312A

  • Method for detecting concentration of antidepressant drugs in serum by using ultra-high performance liquid chromatography-tandem mass spectrometry technology

    CN111812222A